Maxwell Biosciences' MXB-22,510-SC Receives FDA QIDP Designation for Bacterial and Fungal Pneumonia
核心洞察
The FDA granted Qualified Infectious Disease Product (QIDP) designation to Maxwell Biosciences (搜索)' MXB-22,510-SC (搜索) on May 5, 2026, for community-acquired, hospital-acquired, and ventilator-associated pneumonia (搜索) caused by bacterial or fungal pathogens.
QIDP designation provides Fast Track eligibility, Priority Review, and up to 10 years of market exclusivity, accelerating the development pathway for this investigational parenteral injectable.
MXB-22,510-SC (搜索) is a broad-spectrum Claromer peptidomimetic tested by the U.S. military against more than 400 bacterial and fungal pathogens, including drug-resistant strains.
Maxwell Biosciences (搜索), a preclinical-stage biotechnology company developing immune-inspired anti-infective therapeutics, announced that the U.S. Food and Drug Administration (FDA) granted Qualified Infectious Disease Product (QIDP) designation on May 5, 2026, to MXB-22,510-SC (搜索), its investigational parenteral injectable drug candidate for the treatment of community-acquired pneumonia (搜索) (CAP) and hospital-acquired (HAP) or ventilator-associated pneumonia (搜索) (VAP) caused by confirmed or suspected bacterial or fungal pathogens.
The designation represents a significant regulatory milestone for Maxwell's proprietary Claromer platform and establishes a defined pathway toward clinical development for the company's first systemic drug candidate.
Regulatory Implications of QIDP Designation
QIDP designation is available to antibacterial and antifungal drugs intended to treat serious or life-threatening infections. The designation provides FDA Fast Track designation upon sponsor request and FDA Priority Review, which together enable a faster drug development pathway and an expedited FDA review timeline. In addition, the designation permits a total of 10 years of market exclusivity after FDA approval.
For pneumonia (搜索) patients in urgent need, MXB-22,510-SC (搜索) would allow medical professionals to rapidly treat suspected pneumonia cases before diagnostics identify whether the pathogen is bacterial or fungal.
Mechanism of Action and Broad-Spectrum Profile
MXB-22,510-SC (搜索) is the nature-inspired, lead systemic candidate from Maxwell's proprietary Claromer drug platform. Claromers are synthetic, thermally-stable, protease-resistant, low-molecular-weight peptidomimetics inspired by the pathogen-targeting functions of the human innate immune system. The candidate is designed to act directly on structural membrane features shared across almost all pathogen membranes, supporting broad activity against bacterial and fungal species, including drug-resistant pathogens.
"Patients with severe pneumonia (搜索) frequently require urgent treatment before the causative pathogen is known," said Scotch McClure, Founder, Chairman & Chief Executive Officer of Maxwell Biosciences (搜索). "This designation directly aligns with the central objective of MXB-22,510-SC (搜索): a hyper broad-spectrum, direct-acting drug candidate successfully tested by the U.S. military (NMRC, WRAIR_ET and others) against more than 400 bacterial and fungal pathogens, designed to address both bacterial and fungal disease across major unmet medical needs. If successful in clinical development, MXB-22,510-SC could help physicians treat serious infections earlier and more effectively, with the potential to save many lives."
Commercialization and Development Strategy
Maxwell is working with EY's strategy consulting arm, EY-Parthenon (搜索), to formulate the global development and commercialization strategy for MXB-22,510-SC (搜索), including market prioritization, clinical-development pathways, regional and global licensing opportunities, and potential strategic partnerships with pharmaceutical companies.
"The breadth of this QIDP designation strengthens the strategic development profile of MXB-22,510-SC (搜索) across severe pneumonia (搜索) settings," said Sumeet Chandna, Partner at EY-Parthenon (搜索). "This drug candidate has the potential to address one of the largest global public health challenges at scale, save lives and expand access to effective therapies—especially in developing markets."
Maxwell is advancing MXB-22,510-SC (搜索) toward FDA human clinical trials and plans to provide further updates as regulatory and development milestones are reached. The company's Claromer platform comprises synthetic, biostable peptidomimetics designed to target conserved structural features of bacteria, fungi, enveloped viruses and biofilms, with lead programs being developed in parenteral, intranasal, oral and topical formulations for serious infectious diseases.